The current research provides a thorough overview of the CD market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.
Report Includes
- An overview of the global chagas disease (T. cruzi infection) market
- Analyses of the global market trends, with historical market revenue from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the market size and revenue forecast for global chagas disease market, and corresponding market share analysis based on the product type, treatment, and region
- Overview of the significant driving trends and challenges that affect the global market and its vendor landscape
- Review of the epidemiology of chagas disease and potential of key marketed drugs and recent approvals
- Discussion of sustainability trends and factors in the chagas disease market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed
- Analysis of the competitive intelligence based on recent developments, key financials and segmental revenues, and product launch strategies
- Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses
Table of Contents
Chapter 1 Introduction- Overview
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Segmentation Breakdown
Chapter 3 Market Overview
- History
- Trypanosoma Cruzi
- Vector and T. cruzi
- Transmission Routes
- Clinical Forms
- Future Perspectives
- Novel Drugs
- Overview
- Benznidazole
- Toxicity of Benznidazole
- Nifurtimox
- Toxicity of Nifurtimox
- Overview
- Serology (Antibody Detection)
- Molecular Testing
- Competitive Analysis
- BAYER AG
- INSUD PHARMA
List of Tables
Table 1: Novel Drugs for Chagas Disease Treatment
Table 2: Drugs for Chagas Disease
Table 3: Bayer AG: Company Snapshot
Table 4: Bayer AG: Annual Revenue, 2021 and 2022
Table 5: Bayer AG: News
Table 6: Insud Pharma: Company Snapshot
Table 7: Insud Pharma: News
Table 8: Acronyms Used in This Report
List of Figures
Summary Figure: Life Cycle of Trypanosoma Cruzi
Figure 1: Bayer AG: Annual Revenue, 2021 and 2022
Figure 2: Bayer AG: Revenue Shares, by Business Unit, 2022
Figure 3: Bayer AG: Revenue Shares, by Region, 2022
Companies Mentioned
- Bayer Ag
- Insud Pharma
